RT Journal Article
SR Electronic
T1 Tear antibodies to SARS-CoV-2: implications for transmission
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.02.21261479
DO 10.1101/2021.08.02.21261479
A1 Selva, Kevin J.
A1 Davis, Samantha K.
A1 Haycroft, Ebene R.
A1 Lee, Wen Shi
A1 Lopez, Ester
A1 Reynaldi, Arnold
A1 Davenport, Miles P.
A1 Kent, Helen E.
A1 Juno, Jennifer A.
A1 Chung, Amy W.
A1 Kent, Stephen J.
YR 2021
UL http://medrxiv.org/content/early/2021/08/04/2021.08.02.21261479.abstract
AB Objectives SARS-CoV-2 can be transmitted by aerosols and the ocular surface may be an important route of transmission. Little is known about protective antibody responses to SARS-CoV-2 in tears after infection or vaccination. We analysed SARS-CoV-2 specific IgG and IgA responses in human tears after either COVID-19 infection or vaccination.Methods We recruited 16 subjects with COVID-19 infection an average of 7 months previously and 15 subjects before and 2 weeks after Comirnaty (Pfizer-BioNtech) vaccination. Plasma, saliva and basal tears were collected. Pre-pandemic plasma, saliva and basal tears from 11 individuals were included as healthy controls. Antibody responses to 5 SARS-CoV-2 antigens were measured via multiplex.Results IgG antibodies to Spike and Nucleoprotein were detected in tears, saliva and plasma from subjects with prior SARS-CoV-2 infection in comparison to uninfected controls. While RBD-specific antibodies were detected in plasma, minimal RBD-specific antibodies were detected in tears and saliva. In contrast, high levels of IgG antibodies to Spike and RBD, but not Nucleoprotein, were induced in tears, saliva and plasma of subjects receiving 2 doses of the Comirnaty vaccine. Increased levels of IgA1 and IgA2 antibodies to SARS-CoV-2 antigens were detected in plasma following infection or vaccination, but were unchanged in tears and saliva.Conclusion Both infection and vaccination induce SARS-CoV-2-specific IgG antibodies in tears. RBD-specific IgG antibodies in tears were induced by vaccination but were not present 7 months post-infection. This suggests neutralising antibodies may be low in the tears late following infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Victorian government, the Medical Research Future Fund (MRFF) to JAJ, AWC, SJK and Emergent Ventures Fast Grant to AWC. MPD, JAJ, AWC and SJK are supported by NHMRC FellowshipsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent; the study was approved by the University of Melbourne human research and ethics committee (2056689 and 21198153983).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe source data underlying Figure 1–2 and Table 1 are provided as a source data file. All other data are available from the authors upon request.